Sarepta reports preliminary FY23 net product revenue $1.145B

Fourth quarter and full-year 2023 net product revenue for ELEVIDYS are expected to be approximately $131.3M and $200.4M, respectively. Sarepta’s expected net product revenue does not include collaboration revenue. Fourth quarter and full-year 2023 net product revenue for Sarepta’s RNA-based PMOs are expected to be approximately $234.3M and $945M, respectively. Sarepta’s expected net product revenue does not include collaboration revenue. As of December 31, 2023, the company had preliminary cash, cash equivalents, restricted cash and investments of approximately $1.7B. “2023 was a consequential year for Sarepta and the patients we serve, highlighted by the approval, launch and performance of ELEVIDYS, the first gene therapy to treat Duchenne, and the continued performance of our PMOs, EXONDYS 51, VYONDYS 53, and AMONDYS 45,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics.